...
首页> 外文期刊>American Journal of Physiology >Cardiac proteasome activity in muscle ring finger-1 null mice at rest and following synthetic glucocorticoid treatment.
【24h】

Cardiac proteasome activity in muscle ring finger-1 null mice at rest and following synthetic glucocorticoid treatment.

机译:在静止和合成糖皮质激素治疗后,无名指肌肉无名鼠的心肌蛋白酶活性。

获取原文
获取原文并翻译 | 示例
           

摘要

Muscle ring finger-1 (MuRF1) is a muscle-specific E3 ubiquitin ligase that has been implicated in the regulation of cardiac mass through its control of the ubiquitin proteasome system. While it has been suggested that MuRF1 is required for cardiac atrophy, a resting cardiac phenotype has not been reported in mice with a null deletion [knockout (KO)] of MuRF1. Here, we report that MuRF1 KO mice have significantly larger hearts than age-matched wild-type (WT) littermates at >/= 6 mo of age and that loss of cardiac mass can occur in the absence of MuRF1. The objective of this study was to determine whether changes in proteasome activity were responsible for the cardiac phenotypes observed in MuRF1 KO mice. Cardiac function, architecture, and proteasome activity were analyzed at rest and following 28 days of dexamethasone (Dex) treatment in 6-mo-old WT and MuRF1 KO mice. Echocardiography demonstrated normal cardiac function in the enlarged hearts in MURF1 KO mice. At rest, heart mass and cardiomyocyte diameter were significantly greater in MuRF1 KO than in WT mice. The increase in cardiac size in MuRF1 KO mice was related to a decrease in proteasome activity and an increase in Akt signaling relative to WT mice. Dex treatment induced a significant loss of cardiac mass in MuRF1 KO, but not WT, mice. Furthermore, Dex treatment resulted in an increase in proteasome activity in KO, but a decrease in WT, mice. In contrast, Akt/mammalian target of rapamycin signaling decreased in MuRF1 KO mice and increased in WT mice in response to Dex treatment. These findings demonstrate that MuRF1 plays an important role in regulating cardiac size through alterations in protein turnover and that MuRF1 is not required to induce cardiac atrophy.
机译:肌肉无名指1(MuRF1)是一种肌肉特异性E3泛素连接酶,通过控制泛素蛋白酶体系统参与了心脏质量的调节。虽然有人提出,MuRF1是心脏萎缩所必需的,但尚未报道在MuRF1缺失为空[敲除(KO)]的小鼠中有静止的心脏表型。在这里,我们报告说,在年龄> / = 6 mo时,MuRF1 KO小鼠的心脏比年龄匹配的野生型(WT)同窝幼鼠大得多,并且在没有MuRF1的情况下会发生心脏质量下降。这项研究的目的是确定蛋白酶体活性的变化是否与在MuRF1 KO小鼠中观察到的心脏表型有关。在6个月大的WT和MuRF1 KO小鼠中,在静息时和地塞米松(Dex)治疗28天后,分析了心脏功能,结构和蛋白酶体活性。超声心动图显示MURF1 KO小鼠的扩大心脏中的正常心脏功能。静止时,MuRF1 KO中的心脏质量和心肌细胞直径显着大于野生型小鼠。与WT小鼠相比,MuRF1 KO小鼠心脏大小的增加与蛋白酶体活性的降低和Akt信号传导的增加有关。右旋糖治疗在MuRF1 KO小鼠中引起了心脏质量的重大损失,但未引起WT小鼠。此外,Dex处理导致KO蛋白酶体活性增加,而WT小鼠减少。相反,响应Dex处理,在MuRF1 KO小鼠中雷帕霉素信号传导的Akt /哺乳动物靶标降低,而在WT小鼠中则升高。这些发现表明,MuRF1在蛋白质更新中通过改变心脏大小发挥重要作用,并且不需要MuRF1来诱发心脏萎缩。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号